Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment.
Giuseppe MiloneSalvatore LeottaGiulia GiuffridaGiulio Antonio MiloneGabriele SapuppoGiuliana GiuntaBenedetta EspositoDario LeottaSebastiano FioreChiara PennisiLinda LongoAlessandra CupriPublished in: Bone marrow transplantation (2023)
We conducted a prospective study aimed at investigating the prognostic value of the dynamic of a-GVHD progression from cutaneous to visceral involvement. In 108 consecutive patients who underwent allogeneic HSCT, we classified a-GVHD according to a "GHVD skin dynamic": 18/82 patients started Corticosteroid (CS) within 48 h (Group 1); 13/82 started CS within days 3-7 (Group 2); Group 3A (n 31) was defined when Skin GVHD Overall Grade 1, left untreated for 1 week, showed an increase in involved body surface area <5 %; Group 3B (n 20), was defined when Skin GVHD Overall Grade 1, left untreated at 1 week, had an increase in involved body surface area >5%. These four groups had distinctive 2-y OS. Patients could be then grouped into "poor risk" (Group 1 and Group 3B) and "good risk" (Group 2 and Group 3A). "Poor risk" had inferior OS in univariate and multivariate analysis, (HR 2.222; 95% CL: 1.017-4.855; p 0.04). Among the patients with skin-only Grade 1 GVHD, subgroup 3A had an OS of 75.1% versus 39.8% found in subgroup 3B (p = 0.03). The dynamic of skin GVHD may be used to classify a-GVHD and guide treatment in Overall Grade 1 skin-only GVHD.
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- soft tissue
- ejection fraction
- newly diagnosed
- chronic kidney disease
- wound healing
- prognostic factors
- peritoneal dialysis
- machine learning
- randomized controlled trial
- acute myeloid leukemia
- clinical trial
- low dose
- type diabetes
- adipose tissue
- deep learning
- intensive care unit
- insulin resistance
- open label
- acute respiratory distress syndrome
- hematopoietic stem cell